Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Merck's Discount Comes At A Price

There are very few cheap pharma companies these days, which basically means that investors need to either be willing to take on more risk or accept lower returns. With some recent pipeline setbacks and a patent expiration pressuring 2013 results, it's not necessarily easy to make the case for investing in Merck (NYSE:MRK). I believe the market may be underrating that pipeline, however, as well as management's willingness to get a little more aggressive in seeking out near-term growth. With a relatively undemanding valuation, Merck may not offer huge upside, but it does look like something of a bargain in the space.

Decent Results For Q4, But Details Matter

On the surface, Merck's fourth quarter results looked pretty...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details